What was the major news regarding Thermo Fisher Scientific (NYSE:TMO)?

Thermo Fisher announced it is selling its microbiology business to Astorg, a European private equity firm, for approximately $1.075 billion. The deal consists of a cash payment plus a $50 million seller note and is expected to close in the second half of 2026.

What exactly does the divested microbiology business do?

The unit specializes in culture media solutions and antimicrobial susceptibility testing, which fall under the Specialty Diagnostics segment. These tools are critical for clinical diagnostics, pharmaceutical quality control, and testing for food safety across the global supply chain.

How much revenue does this business contribute to Thermo Fisher (NYSE:TMO)?

In 2025, the microbiology business generated approximately $645 million in revenue. While significant, this divestiture represents a strategic move by Thermo Fisher to streamline its portfolio, likely focusing on higher-growth or higher-margin segments within its broader life sciences ecosystem.

What is the expected impact on earnings for Thermo Fisher (NYSE:TMO) shareholders?

Management expects the sale to be dilutive to adjusted earnings per share (EPS) by approximately $0.15 in the first full year after the deal closes. This means short-term earnings will likely be lower as the company loses the income from this unit before potentially redeploying the cash.

Why is Thermo Fisher (NYSE:TMO) selling a profitable business unit?

While the article does not explicitly state management's motive, such moves are typically part of a strategy to exit mature, lower-growth markets to focus on high-tech areas like proteomics or bioproduction. Selling to a private equity firm like Astorg allows Thermo Fisher to offload the specialized assets for a significant cash infusion of over $1 billion.

Thermo Fisher to divest microbiology business to Astorg for $1.075B

Written by Mahathir BayenaPublished Apr. 27 2026Last Updated Apr. 27 2026

Thermo Fisher Scientific (NYSE:TMO) announced on Monday that it has entered into a definitive agreement to sell its microbiology business to Astorg, a prominent pan-European private equity firm.

The transaction is valued at approximately $1.075 billion, comprised of a cash payment and a $50 million seller note.

The microbiology unit, which operates within Thermo Fisher’s Specialty Diagnostics segment, is a leading provider of culture media solutions and antimicrobial susceptibility testing.

These products are essential for clinical diagnostics, pharmaceutical quality control, and food safety testing.

In 2025, the business generated approximately $645 million in revenue, reflecting its significant role in the global laboratory supply chain.

Thermo Fisher expects the divestiture to be dilutive to adjusted earnings per share by approximately $0.15 in the first full year following the completion of the sale.

The deal is slated to close in the second half of 2026, contingent upon regulatory approvals and customary closing conditions.